OBJECTIVE To explore the drug resistance rate and risk factor of Pseudomonas aeruginosa against ceftazidime in a certain hospital,and provide scientific basis for preventing the P.aeruginosa infections.METHODS A total of 109 P.aeruginosa strains,which were isolated from sputum cultures in patients in a certain hospital in 2005,were identified with VITEK GNI+ automation system.The possible risk factors and underlying diseases were investigated by reviewing patients′ medical records.Multiple Logistic regression models were used for statistical analyses by SPSS software(13.0).RESULTS The resistant ratios against ceftazidime was 38.5%.P.aeruginosa resistant ratios in ICU and the neurosurgery ward were 78.57% and 54.84%,respectively,and higher than others.Treatment days before infection in hospital(over two days),staying at the ICU or neurosurgery ward,using breathing machine,were associated with the sensitivity to ceftazidime for P.aeruginosa.CONCLUSIONS In order to prevent and reduce the drug resistant ratios for P.aeruginosa,we should pay more attention to the patients admitted in ICU and neurosurgery wards.Risk factors,such as treatment days in hospital,living in different wards and using breathing machine,were associated with the resistant ratios for P.aeruginosa against ceftazidime.

135 ms in selecting patients for cardiac resynchronization therapy(CRT).Methods Forty-five patients with SHF were randomly divided into two groups according to QRS width: Group 1(QRS width 135 ms could finely predict the presence of interventricular dyssynchrony,with a sensitivity of 80% and a specificity of 87.5%;while the same cutoff value to predict intraventricular dyssynchrony only yielded a sensitivity of 44.1% and specificity of 73.6%.Conclusion Intraventricular dyssynchrony and(or) interventricular dyssynchrony has a high prevalence in patients with SHF.A QRS duration cutoff value higher 135 ms can well evaluate the cardiac mechanical dyssynchrony in clinical practice,which may be of value for optimizing selection of CRT candidates and reducing the nonresponders.

Objective: To observe the influence of sotalol on the QT dispersion in patients with atrioventricular accessory pathways underwent radiofrequency catheter ablation (RFCA). Methods: Thirty six patients were divided into 2 groups by random. One was the drug group(18 cases) treated by RFCA, and sotalol 160 mg was orally administered and intracardiac electrophysiological study was performed every 30 min for 5 times. The other group(control group, 18 cases) only treated by RFCA.QTd,QTcd and QTLcd were measured before and after RFCA. Results: There was no significant difference with QT dispersion before and after RFCA in control group. When compared with before RFCA, QTd in patients administered sotalol was (30.9?14.3) ms vs (24.7?9.6) ms; QTcd(33.7?17.1) ms vs (25.2?10.1) ms; QTLcd(30.8?14.1)ms vs (25.6?19.4) ms ( P

Objective: To observe the influence of sot alol on the QT dispersion in patients with atrioventricular accessory pathways u nderwent radiofrequency catheter ablation (RFCA). Methods: Thirt y-six patients were divided into 2 groups by random. One was the drug group(18 cases) treated by RFCA， and sotalol 160 mg was orally administered and intracar diac electrophysiological study was performed every 30 min for 5 times. Th e other group(control group, 18 cases) only treated by RFCA.QTd,QTcd and QTLcd w ere measured before and after RFCA. Results: There was no signif icant difference with QT dispersion before and after RFCA in control group. When compared with before RFCA, QTd in patients administered sotalol was (30.9 ±14.3) ms vs (24.7±9.6) ms; QTcd(33.7±17.1) ms vs (25.2±10.1) ms; QT Lcd(30.8±14.1)ms vs (25.6±19.4) ms (P<0.05). Conclusion: Sotalol can slightly lower QT dispersion, which is beneficial for preventing malignant ventricular arrthythmia. It is safe in RFCA in pateints with accessory pathway.

For the high cost and mobility issues, a home uterine contraction pressure monitoring system based on Windows CE platform was developed. In this paper, the design of hardware circuit, micro-controller system and LabVIEW program based on Windows CE are discussed. The clinical validation experiment in hospital for this system was made and the experimental results show that this system complies with the trend that current medical equipment is becoming portable, homely and networked. Through real-time monitoring uterine contraction pressure, occurrence of premature birth and abortion can be prevented effectively.
Female ; Humans ; Monitoring, Physiologic ; instrumentation ; Pregnancy ; Uterine Contraction

0.05). The marks of the group of CBL in case analysis test and clinical skills test are significantly higher than that of the group of stepwise learning (P

Objective To observe the effects of pressure control ventilation with volume guar-antee (PCV-VG)on the pulmonary function during percutaneous nephrolithotomy procedures in pa-tients with general anesthesia.Methods Forty patients scheduled for percutaneous nephrolithotomy were selected and randomly allocated into PCV-VG group (n =20)and volume controlled ventilation (VCV)group (n =20).For two modes of ventilation,the goal tidal volume was 6-8 ml/kg,and the respiratory rate was contralled to 12-20 bpm.PA-a O 2 ,OI,RI,Ppk,Pmean,Cst,Hct,Lac were re-corded at intubation (T0 ),1 5 min (T1 ),30 min (T2 ),60 min (T3 ),and 120 min (L4 )after intuba-tion.Results PCV-VG resulted in significantly lower PA-a O 2 ,RI,Ppk,Pmean compared with VC ventilation (P < 0.05 or P < 0.01 ),and significantly higher OI,Cst versus VC ventilation (P <0.05 or P < 0.01).Conclusion In general anesthesia patients undergoing percutaneous nephrolithoto-my,PCV-VG is superior to VCV in terms of lower airway pressure and more stable hemodynamics, thus protects pulmonary function.

Objective To study the clinical effectiveness of low cut and five dissector thyroidectomy to treat hyperthyroidism.Methods 337 cases of hyperthyroidism were randomly divided into study group(low cut and five dissector technique,223 cases) and control group(traditional technique,114 cases) according to the ratio of two:operating time,bleeding,complications,recur were compared between these two groups.Results The operating time of the study group and control group were(66.33?25.11)min and(121.27?42.35)min(t=12.75,P0.05).The rate of recurrence was marked(P

Objective: To investigate the effects of pravastatin o n atherosclerotic plaque and cardiovascular events. Methods: Fifty- seven patients with coronary artery disease (44 male and 13 female, 58.4±11.3 y ears) were randommized into pravastatin and control groups. The patients in prav astatin group were administered 10 mg of pravastatin from the night of coronary angiography day. After 7.3 months (mean) of follow-up, plasma lipid parameters and coronary angiograph were repeated. Results: (1) A favorable effect on plasma lipid parameters was found. After administration, total choles terol(TC), low density lipoprotein cholesterol (LDL-C) and triglyceride(TG) red uced by 15.0% (P<0.01), 18.0% (P<0.01) and 6.0%, respectively. High den s ity lipoprotein cholesterol(HDL-C) increased by 10.6%. However, in control grou p, TC and LDL-C showed a tendency to reduce, but no significant difference was found between those of pre- and post-administration. (2)There was no significa nt difference in luminal diameter between pre- and post-administration in both groups. (3) Cardiovascular events in pravastatin group was significantly lower than those in control (P<0.05). (4) Pravastatin had no significant effect on HR, BP and left ventricular ejection fraction in both groups. Conclusio n: Pravastatin can stabilize coronary atherosclerostic plaque and reduce the incidence of cardiovascular events by improving plasma lipid parameters.

Objective: To evaluate the immunogenicity of HIV-1 clade C/B’ vaccine based on modified vaccinia virus Ankara (MVA) vector in mice. Methods: Mice were inoculated with 3-dose HIV vaccine by intramuscular injection. Blood sample were collected every second week, and then the antibodies against HIV were detected. At week 6, mice were killed and cellular immune responses were examined by ELISPOT. Result: The number of spot forming cells in the 107 pfu/ml -dose group was more than those of 105 pfu/ml -dose and 106 pfu/ml -dose groups significantly. HIV specific antibodies emerged at week 2 and elevated rapidly at week 4 and week 6. The level of specific IgG in the 107 pfu/ml -dose group was more than those of 105 pfu/ml -dose and 106 pfu/ml -dose groups significantly. Conclusion: The ADMVA induces both humoral immunoresponse and cellular immune responses.